Follow on Google News News By Tag Industry News Country(s) Industry News
Follow on Google News | BioScience Market Report on PWRM.OB, NEPT, ASTM from CRWE Wallstreet.Power3 Medical Products (OTCBB- PWRM.OB) NuroPro Blood Test is diagnostic tool for the early detection of Neurodegenerative diseases.
By: Lynn Lansky PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS (Lou Gehrig’s disease), Alzheimer’s, Parkinson’s diseases, breast cancer, and drug resistance. Neptune Technologies & Bioressources Inc. today reports its consolidated financial results for the three-month period ended May 31, 2010, appoints IR firm and updates on options and warrants. Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Aastrom Biosciences, Inc. , the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM). The extension study is designed to offer control-group patients from the IMPACT-DCM trial the opportunity to receive treatment with an expanded mixture of their own bone marrow-derived stem and progenitor cells after completing at least 6 months of follow-up. Sign Up For Free Stock Alerts At http://crwewallstreet.com/ ************************************************************ THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!Disclaimer: End
Account Email Address Disclaimer Report Abuse
|
|